research Post-marketing safety profile of cladribine in multiple sclerosis: a disproportionality analysis based on the FDA adverse event reporting system
Cladribine has known risks and potential new safety concerns, requiring careful monitoring.
Search
for
Sort by
Research
480-510 / 1000+ results 
research The difficulty of finding ‘healthy’ volunteers
Most people who volunteered for a health study had medical issues, showing the need for careful screening before trials.
research 014 Tyrosine Kinase 2 Inhibition Ameliorates the Phenotype of Lesional Alopecia Areata Scalp Skin Ex Vivo, and Reverses the Induction of Human Alopecia Areata in a Humanized Mouse Model
TYK2 inhibition may help treat alopecia areata by promoting hair growth and reducing immune response.
research Profile analysis of adverse events after boron neutron capture therapy for head and neck cancer: a sub-analysis of the JHN002 study
Boron neutron capture therapy for head and neck cancer can cause side effects like mouth sores and skin irritation, which vary depending on where the treatment is aimed.
research Duration of current alopecia areata episode predicts the effectiveness of baricitinib in Japanese patients with alopecia areata: a single-center retrospective study
Shorter alopecia areata episodes lead to better baricitinib treatment outcomes.
research Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
Deuruxolitinib effectively promotes hair regrowth in adults with alopecia areata.
research ODAC Votes No on IntraDose Injectible Cisplatin/Epinephrine Gel for Head and Neck Cancer
The committee decided not to approve the drug due to low effectiveness and high risks.
research Baricitinib Achieved Complete/Near Complete Scalp Coverage in SALT Score ≤20 Responders: 52-Week Findings From BRAVE-AA Trials
Baricitinib significantly regrows hair in severe alopecia areata patients.
research Moving Beyond Boundaries: Utilization of Longitudinal Exposure–Response Model for Bounded Outcome Score to Inform Decision Making in the Accelerated Drug Development Paradigm
A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.
research Sex differences in clinical trials of ALRV5XR treatment of androgenetic alopecia and telogen effluvium
ALRV5XR effectively promotes hair regrowth in both men and women through different mechanisms.
research Development of Uniform Protocol for Alopecia Areata Clinical Trials
A standard protocol for alopecia areata clinical trials was created to improve consistency and encourage more research.
research The Efficacy and Safety of AP-FHG0604T on Female Pattern Hair Loss: A Randomized Double-blind Placebo-controlled Clinical Trial
research Sacituzumab tirumotecan (sac-TMT/MK-2870/SKB264): a novel antibody–drug conjugate in breast cancer
Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.
research Improvement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regrowth with Baricitinib
Baricitinib improves quality of life and reduces anxiety and depression in severe alopecia areata patients with hair regrowth.
research There are early, gradual and late responders for scalp hair regrowth in patients with alopecia areata treated with baricitinib
Different people with severe hair loss respond to baricitinib treatment at different times, with some showing improvement early, some gradually, and others later.
research VEPA and ML-Y1 Regimen for Elderly Non-Hodgkin's Lymphoma.
Both VEPA and ML-Y1 treatments are not effective enough for elderly non-Hodgkin's lymphoma patients.
research Discrepancies in safety reporting for chronic back pain clinical trials: an observational study from ClinicalTrials.gov and publications
Inconsistent safety reporting in chronic back pain trials risks patient safety and decision-making.
research Ivarmacitinib stimulates hair regrowth in severe alopecia areata
Ivarmacitinib effectively regrows hair in severe alopecia areata.
research A Multi‐Center Clinical Trial to Evaluate the Efficacy of the Next Generation TriHex Technology Antiaging Regimen
The serum improves facial skin quality safely and effectively.
research Safety and efficacy of a novel skin lightening agent for melasma
The new treatment was safe and may effectively treat male pattern hair loss.
research Treatment of androgenetic alopecia in females in reproductive age with topical estradiolbenzoate, prednisolon and salicylic acid.
The treatment slightly increased hair growth and was safe for most women.
research Proxalutamide (GT0918) Reduces the Rate of Hospitalization in mild-to-moderate COVID-19 Female Patients: A Randomized Double-Blinded Placebo-Controlled Two-Arm Parallel Trial
Proxalutamide significantly lowered hospitalization rates in women with mild-to-moderate COVID-19.
research Proxalutamide Improves Inflammatory, Immunologic, and Thrombogenic Markers in Mild-to-Moderate COVID-19 Males and Females: an Exploratory Analysis of a Randomized, Double-Blinded, Placebo-Controlled Trial Early Antiandrogen Therapy (EAT) with Proxalutamide (The EAT-Proxa Biochemical AndroCoV-Trial)
Proxalutamide improved blood markers related to inflammation, immune response, and clotting in COVID-19 patients, potentially reducing hospitalizations.
research EX VIVO DRUG SENSITIVITY EVALUATION OF A RARE ZMYM2::FGFR1+ LEUKEMIA PATIENT
Pemigatinib may be effective for treating ZMYM2::FGFR1 fusion-positive leukemia.
research Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer
Pegylated liposomal doxorubicin is as effective as conventional doxorubicin but causes fewer heart problems and side effects.
research 24. 力発揮および操作性からみた下肢運動の一側優位性(神経・感覚,一般口演,第63回日本体力医学会大会)
Men with early-onset hair loss are less responsive to bromocriptine's heart and metabolism benefits.
research A qualitative phase I study protocol on developing patient-reported outcome measure for hair, scalp, eyebrows, eyelashes, and beard-related skin disorders
The goal is to create a tool for patients to report their experiences with various hair and scalp disorders.
research 290 Brepocitinib improves cicatricial alopecia and downregulates key T-helper biomarkers
Brepocitinib improves cicatricial alopecia and reduces key immune markers.
research Feasibility and tolerability of eribulin-based chemotherapy versus other chemotherapy regimens for patients with metastatic triple-negative breast cancer: a single-centre retrospective study
Eribulin-based chemotherapy is more effective and has fewer side effects for advanced triple-negative breast cancer.
research Gemcitabine combined with either pemetrexed or paclitaxel in the treatment of advanced non-small cell lung cancer
Combining gemcitabine with paclitaxel is more effective than with pemetrexed for advanced lung cancer.